<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00522990</url>
  </required_header>
  <id_info>
    <org_study_id>AT9283/0002</org_study_id>
    <secondary_id>2006-0177</secondary_id>
    <nct_id>NCT00522990</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias</brief_title>
  <official_title>A Phase I/IIa Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of AT9283, a Small Molecule Inhibitor of Aurora Kinases, in Patients With Refractory Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astex Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astex Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to find the highest tolerable dose of AT9283 that&#xD;
      can be given to patients who have ALL, AML, CML, high-risk myelodysplastic syndromes, or&#xD;
      myelofibrosis with myeloid metaplasia. Researchers want to perform pharmacokinetic (PK)&#xD;
      testing on blood to find out how quickly the study drug leaves the body and how the body&#xD;
      breaks down the drug. The safety and effectiveness of this drug will also be studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dose escalation study of AT9283 administered to patients with refractory hematological&#xD;
      malignancies. Study objectives include identification of MTD and dose limiting toxicities,&#xD;
      preliminary assessment of efficacy and definition of pharmacokinetic profile&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recommended Phase II dose determined&#xD;
  </why_stopped>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Up to 30 days after completing therapy with AT9283</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile, Safety and tolerability of maximum tolerated dose, efficacy, pharmacodynamic effect, identify dose limiting toxicities</measure>
    <time_frame>Within six months of initiating therapy with AT92823</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Chronic Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Refractory Hematological Malignancies</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT9283</intervention_name>
    <description>Three weekly intravenous administration of AT9283</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed written informed consent&#xD;
&#xD;
          2. Histological or cytological confirmation of one of the following:&#xD;
&#xD;
             Relapsed or refractory AML or ALL; acute leukaemia in patients who are unsuitable for&#xD;
             or refuse standard therapy&#xD;
&#xD;
             CML in chronic phase, accelerated phase or blast crisis that is resistant or&#xD;
             refractory to standard therapy&#xD;
&#xD;
             High-risk MDS, defined as the presence of:&#xD;
&#xD;
             i)Refractory anemia with excess blasts (RAEB, 5-19% bone marrow blasts)&#xD;
&#xD;
             or&#xD;
&#xD;
             ii)RAEB in transformation to AML (RAEBT with 20-30% bone marrow blasts)&#xD;
&#xD;
             Advanced MMM defined by the presence of one or more of the following features:&#xD;
&#xD;
             i)Hemoglobin &lt; 10 gm/dL (100 g/L)&#xD;
&#xD;
             ii)Platelet count &lt; 100 x 109/L&#xD;
&#xD;
             iii)White blood cell count &lt; 4 x 109/L&#xD;
&#xD;
             iv)Symptomatic splenomegaly or other disease-related symptoms inadequately controlled&#xD;
             by conventional therapies&#xD;
&#xD;
          3. ECOG performance status 0, 1 or 2&#xD;
&#xD;
          4. Male or female, age 18 years or older&#xD;
&#xD;
          5. Negative pregnancy test or history of surgical sterility or evidence of&#xD;
             post-menopausal status (post-menopausal status is defined as any of the following:&#xD;
             natural menopause with menses &gt;1 year ago; radiation induced oophorectomy with last&#xD;
             menses &gt;1 year ago; chemotherapy induced menopause with 1 year interval since last&#xD;
             menses&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inadequate liver function as demonstrated by serum bilirubin ≥1.5 times the upper&#xD;
             limits of reference range (ULRR) or alanine aminotransferase (ALT) or aspartate&#xD;
             aminotransferase (AST) or alkaline phosphatase (ALP) ≥2.5 times the ULRR (or ≥5 times&#xD;
             the ULRR in the presence of liver metastases)&#xD;
&#xD;
          2. Impaired renal function as demonstrated either by an isolated creatinine value of ≥1.5&#xD;
             times the ULRR OR creatinine clearance &lt; 50 mL/min determined by Cockcroft-Gault&#xD;
             formula. Note there is no requirement to determine a formal creatinine clearance if&#xD;
             the patient's serum creatinine value is ≥1.5 times the ULRR.&#xD;
&#xD;
          3. Radiotherapy or chemotherapy within the 14 days prior to the first dose of AT9283&#xD;
             being administered (Day 1, dose level 1). Planned use of hydroxyurea other than as is&#xD;
             permitted as described in section 11.9.&#xD;
&#xD;
          4. Receiving an investigational anti-cancer treatment concurrently or within 14 days&#xD;
             prior to the start of AT9283 infusion (Day 1)&#xD;
&#xD;
          5. Unresolved CTCAE grade 2 or greater toxicity (other than stable toxicity) from&#xD;
             previous anti-cancer therapy excluding alopecia&#xD;
&#xD;
          6. Any evidence of severe or uncontrolled systemic conditions (e.g., severe hepatic&#xD;
             impairment) or current unstable or uncompensated respiratory or cardiac conditions&#xD;
             which makes it undesirable for the patient to participate in the study or which could&#xD;
             jeopardize compliance with the protocol&#xD;
&#xD;
          7. Active, uncontrolled central nervous system disease&#xD;
&#xD;
          8. Ischemic heart disease or myocardial infarction or unstable cardiac disease within 3&#xD;
             months of study entry&#xD;
&#xD;
          9. Prior infection with human immunodeficiency virus (HIV), hepatitis B or C viruses -&#xD;
             screening for viral infections is not required for entry to this study&#xD;
&#xD;
         10. Major surgery within 28 days prior to the start of AT9283 infusion (Day 1) - excluding&#xD;
             skin biopsies and procedures for insertion of central venous access devices&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hagop Kantarjian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas M. D. Anderson Cancer Center (MDACC)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas, MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/24355079</url>
    <description>Publication of the Study Results</description>
  </link>
  <results_reference>
    <citation>Foran J, Ravandi F, Wierda W, Garcia-Manero G, Verstovsek S, Kadia T, Burger J, Yule M, Langford G, Lyons J, Ayrton J, Lock V, Borthakur G, Cortes J, Kantarjian H. A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis. Clin Lymphoma Myeloma Leuk. 2014 Jun;14(3):223-30. doi: 10.1016/j.clml.2013.11.001. Epub 2013 Nov 14.</citation>
    <PMID>24355079</PMID>
  </results_reference>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>August 29, 2007</study_first_submitted>
  <study_first_submitted_qc>August 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2007</study_first_posted>
  <disposition_first_submitted>January 8, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>January 8, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 5, 2016</disposition_first_posted>
  <last_update_submitted>January 8, 2016</last_update_submitted>
  <last_update_submitted_qc>January 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

